What You Should Know:
- Today, digital medicine leader physIQ and CellCarta, a global leader in precision medicine services announced they are collaborating on a groundbreaking study that could revolutionize vaccine development.
- The strategic collaboration advances the detailed study of early, individualized human responses to vaccinations as pharma companies race to deliver safe, effective vaccines sooner.
physIQ, a pioneer in digital medicine, and CellCarta, a global leader in
Read More
PhysIQ
Science 37, physIQ Collaborate to Enhance Clinical Trial Data Collected from Connected Devices
What You Should Know:
- Science 37, a leader in agile clinical trials, and physIQ Inc, a leader in digital medicine, announced their alliance to help researchers use remote biosensors and machine learning to build more robust data sets.
- The partnership will help boost the number of digital biomarkers and generate insights from continuous data streams to indicate the safety and efficacy of new clinical treatments more quickly and objectively.
Read More
Intermountain, UT Health, Rush U Joins PhysIQ’s COVID-19 Digital Biomarker Study
What You Should Know:
- Today, physIQ announced that three more health systems have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. Intermountain Healthcare Utah, The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center will serve as recruiting centers and key partners in the Phase II validation stage of this study.
- Realization of this biomarker may provide early detection of a
Read More
DoD, Duke, John Hopkins, HJF, physIQ Launch 18-Month COVID-19 Clinical Trial Study
What You Should Know:
- Today, PhysIQ Inc. announced its partnership with Johns Hopkins University, Duke University and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), to support a clinical trial to evaluate products for early treatment and post-exposure treatment of COVID-19. The 18-month study will assess disease progression and provide early indication of infection. This DOD-funded initiative will assess the role of continuous biosensor
Read More
Executive Hires: Walgreens Appoints New CEO, Cityblock Health, Innovaccer, Others
Walgreens appoints Rosalind (Roz) Brewer as the company’s Chief Executive Officer, effective on March 15, 2021. Brewer will also join the WBA Board of Directors upon assuming the role. She succeeds Stefano Pessina who, as previously announced, will transition to the role of Executive Chairman of the Board of WBA. Brewer, 58, will become the first Black woman to lead a Fortune 500 company.
Former Livongo President, Jennifer Schneider, has joined Cityblock Health’s Board of
Read More
NIH Taps PhysIQ to Develop AI-Based COVID-19 Digital Biomarker
What You Should Know:
- physIQ has been selected by the National Institute of Health (NIH) to develop an innovative AI-based COVID-19 digital biomarker solution to address the COVID-19 pandemic.
- Early detection of COVID-19 decompensation in patients
is complicated by infrequent and non-specific clinical data. The first-in-kind
tool will collect and analyzes continuous physiologic data could provide early
clinical indicators of COVID-19 decompensation.
The National Cancer
Institute
Read More
PhysIQ Expands Patent Portfolio for Artificial Intelligence Analytics in Wearables
- PhysIQ awarded patents for a game-changing deep net approach to estimating functional capacity daily from continuous wearable sensor data.
- PhysIQ’s adds yet another patent to its extensive portfolio on personalized physiology analytics powered by the similarity-based modeling machine learning approach.
PhysIQ continues to
receive recognition for the novelty and value of its technology with the
announcement of two new patent allowances by the US Patent & Trademark
Office on
Read More
PhysIQ Raises $8M to Expand Personalized Physiology Analytics for Patient Insights
PhysIQ, a provider developing solutions that leverage artificial intelligence (AI) to empower digital health for ambulatory patient monitoring and clinical trial support has raised $8 million in Series B funding led by 4490 Ventures. The round also includes participation from Global Health Sciences (GHS) Fund through Quark Venture Inc. and GF Securities, along with existing investor LionBird and others. The company plans to utilize the latest round of funding to support of the commercial launch
Read More
